Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, 960-1295, Japan.
Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Kurume, 830-0011, Japan.
Respir Investig. 2023 Nov;61(6):773-780. doi: 10.1016/j.resinv.2023.08.007. Epub 2023 Sep 21.
Chronic obstructive pulmonary disease (COPD) is characterized by airflow obstruction on spirometry and symptoms such as dyspnea on exertion and chronic cough with sputum production, thus making it a significant healthcare issue worldwide. Japanese patients with COPD have unique characteristics compared to patients in Western countries, including older age and lower exacerbation frequency. The Japanese Respiratory Society (JRS) published the 6th edition of the COPD guideline in June 2022. This article introduces the management goals of COPD and describes its management during the stable phase, as outlined in the guideline. Management goals include improving the current status, such as the symptoms, quality of life (QOL), exercise tolerance, and physical activity, and reducing future risks through prevention of exacerbation and suppression of disease progression to prevent shortening of healthy life expectancy. Management plans should include avoidance of causative substances, assessment of disease severity, and personalized treatment plans. Pharmacotherapy using inhalation bronchodilators is a key component of the treatment of stable COPD. Bronchodilators, including short- and long-acting dilators, are commonly used to relieve symptoms and improve QOL. Inhaled corticosteroids (ICSs) are used in combination with long-acting bronchodilators, especially in patients with asthma and COPD overlap, or those experiencing frequent exacerbation of eosinophilia. Combination therapy with a long-acting muscarinic antagonist (LAMA), a long-acting beta 2 agonist (LABA), and ICS is expected to improve QOL and respiratory function and reduce mortality and exacerbation compared to the LAMA + LABA combination. Non-pharmacological therapies, including smoking cessation and pulmonary rehabilitation, should also be considered.
慢性阻塞性肺疾病(COPD)的特点是肺功能检查显示气流受限,以及运动时呼吸困难和慢性咳嗽伴咳痰等症状,因此成为全球范围内的重大医疗保健问题。与西方国家的 COPD 患者相比,日本患者具有独特的特征,包括年龄更大和发作频率更低。日本呼吸学会(JRS)于 2022 年 6 月发布了第 6 版 COPD 指南。本文介绍了 COPD 的管理目标,并描述了指南中概述的稳定期 COPD 的管理。管理目标包括改善当前状况,如症状、生活质量(QOL)、运动耐量和身体活动,以及通过预防发作和抑制疾病进展来降低未来风险,以防止健康预期寿命缩短。管理计划应包括避免致病物质、评估疾病严重程度和制定个性化治疗计划。使用吸入性支气管扩张剂的药物治疗是稳定期 COPD 治疗的关键组成部分。支气管扩张剂,包括短效和长效扩张剂,常用于缓解症状和改善 QOL。吸入性皮质类固醇(ICSs)与长效支气管扩张剂联合使用,特别是在哮喘和 COPD 重叠患者或频繁发生嗜酸粒细胞增多症的患者中。长效毒蕈碱拮抗剂(LAMA)、长效β2 激动剂(LABA)和 ICS 的联合治疗有望改善 QOL 和呼吸功能,并降低死亡率和发作率,优于 LAMA+LABA 联合治疗。还应考虑非药物治疗,包括戒烟和肺康复。